Omeros announces results for narsoplimab expanded access program
Omeros (OMER) announced statistical analysis results related to the expanded access program for narsoplimab, Omeros’ ...
Omeros Announces Robust Results for Narsoplimab Expanded Access Program in TA-TMA
Omeros Corporation (Nasdaq: OMER) today announced statistical analysis results related to the expanded access program (EAP) for narsoplimab, Omeros’ first-in-class monoclonal antibody inhibiting the ...
Stocktwits on MSN5 天
Solid Biosciences' Retail Following Swells Amid Stock's Best Run In A Year — What's ...
Solid Biosciences Inc. (SLDB) shares surged more than 31% on Tuesday, their best session since January 2024, and extended ...
The Daily Item6 天
Heart disease a risk for everybody to be aware of
Heart disease is the leading cause of death for men, women, and people of most racial and ethnic groups. In fact, according ...
Solid Biosciences reports initial clinical data from INSPIRE DUCHENNE trial
Solid Biosciences (SLDB) announced initial data from the Phase 1/2 INSPIRE DUCHENNE trial evaluating SGT-003, a next-generation gene therapy ...
Solid Biosciences Reports Positive Initial Clinical Data from Next-Generation Duchenne Gene ...
Day 90 biopsy data reported from first 3 participants dosed in Phase 1/2 INSPIRE DUCHENNE trial —— Average microdystrophin ...